For UK Healthcare Professionals Only
Adverse events should be reported. Reporting forms and information can be found at: yellowcard.mhra.gov.uk
Adverse events should also be reported to Aspire Pharma Ltd on +44 (0)1730 231148.

For more information about products within the Pathway Portfolio, please click here for prescribing information

The Pathway Portfolio is Aspire Pharma’s branded generic portfolio with products covering a wide range of therapy areas, including: CNS, Respiratory, Cardiovascular, Pain and Urology.

Each product in the portfolio has its own key offerings, ranging from:

  • A full range of strengths available1
  • A first strength to market1
  • Simpler dosing which may help some patients with concordance and compliance1-2
  • The first brand to market1

Pathway to Partnership:

Trusted Brands:

  • Bioequivalent to brand originators3
  • Available from mainline wholesalers

Bespoke Support:

  • Price guarantee
  • Individualised rebates on request

Our Pathway Portfolio offers a wide range of product support resources, for both healthcare professionals and patients, across a variety of therapeutic areas.

Explore the portfolio

Central Nervous System

Respiratory

Urology

Cardiology

Pain

Learn more about how the Pathway Portfolio can offer your ICB savings

Contact a member of our team

References:

  1. UK Drug Tariff (Accessed June 2026)
  2. Kyoko Higashiet al. Dosing frequency and adherence in chronic psychiatric disease: systematic review and meta-analysis. Neuropsychiatric Disease and Treatment, 2013; 9: 119–131 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3552550/
  3. REF-00061-1 | Bioequivalence Data on File

MAT-UK-XLP-0030-1 | June 2026